Evaluation of Insulin Resistance (HOMA-IR) for Patients with and without Thyroid Nodules: A Patient-Based Study

BACKGROUND: The aim of this study was to assess the prevalence of insulin resistance (HOMA-IR) between patients with and without thyroid nodules.

MATERIALS AND METHODS: This case–control study was performed on 86 patients with normal Thyroid-stimulating hormone (TSH) level (0.5–4.5 mIU/L) with thyroid nodules, who referred to Imam Khomeini and Golestan Hospitals (Ahvaz, Iran).

Furthermore, 43 nonnodule patients with normal TSH level and normal thyroid ultrasonography were recruited from the general population as control group.

The insulin resistance was evaluated for them made and the HOMA-IR ≥2.5 was defined as insulin resistance.

RESULTS: The mean of HOMA-IR value was significantly higher in thyroid nodule patients compared to controls (3.02 ± 1.92 vs. 1.10 ± 1.55; P < 0.001).

Insulin resistance was seen in 49 thyroid nodule patients (57.0%), and 4 patients (9.3%) in the control group (P < 0.0001).

Waist circumference, body mass index, fasting blood sugar, triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and insulin levels were significantly higher in the thyroid nodule group.

CONCLUSIONS: Our study shows there is an association between insulin resistance and thyroid nodules.

The patients with thyroid nodules have higher HOMA-IR value.